Incidence and management of the main adverse effects reported after
COVID-19 vaccination
Abstract
Coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) first appeared in Wuhan,
China in 2019. Soon after, it was declared a pandemic by the World
Health Organization (WHO). The health crisis imposed by a new virus and
its rapid spread worldwide prompted the fast development of vaccines.
For the first time in human history, two vaccines based on recombinant
genetic material technology were approved for human use. These mRNA
vaccines were applied in massive immunization programs around the world,
followed by other vaccines based on more traditional approaches. Even
though all vaccines were tested in clinical trials prior to their
general administration, serious adverse events, usually of very low
incidence, were mostly identified after application of millions of
doses. Probing a direct correlation (the cause-effect paradigm) between
vaccination and the appearance of adverse effects has proven
challenging. This review focuses on anaphylaxis, myocarditis,
vaccine-induced thrombotic thrombocytopenia, Guillain-Barré syndrome and
transverse myelitis reported in the context of COVID-19 vaccination. We
highlight their symptoms and laboratory tests required for an adequate
diagnosis, and briefly outline the recommended treatments. The aim of
the present work is to increase awareness among healthcare personal
about these serious adverse events that may arise post-vaccination.
Regardless of the ongoing discussion about the safety of COVID-19
vaccination, these adverse effects must be identified promptly and
treated effectively to reduce the risk of complications.